Form 4: Protagonist Therapeutics Director Acquires Shares and Options

Harold E. Selick, a director at Protagonist Therapeutics, acquired 5,130 shares of common stock and options to purchase 6,584 shares on January 2, 2025.

Summary

• On January 2, 2025, Harold E. Selick, a director at Protagonist Therapeutics, acquired 5,130 shares of common stock.
• These shares were granted as restricted stock units, which will vest in full on January 15, 2026, contingent on continued service to the company.
• Selick also acquired options to purchase 6,584 shares of common stock at an exercise price of $38.98.
• These options vest in 12 equal monthly installments starting January 2, 2025, also subject to continued service.
• Following these transactions, Selick directly owns 33,126 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard insider transaction, which is generally positive as it shows director commitment, but not a major event.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future.
• The vesting schedule for both the shares and options incentivizes continued service and commitment from the director.

Future Outlook

The vesting schedules for the shares and options suggest a long-term commitment from the director to the company.

Industry Context

This type of transaction is common in the biotech industry, where equity-based compensation is often used to align the interests of management and shareholders.

Comparison to Industry Standards

• Equity grants to directors are a standard practice in the biotech industry, often used to attract and retain talent.
• The vesting schedules are typical, with restricted stock units vesting over a year or more and options vesting over several years.
• The exercise price of $38.98 for the options is a key metric, as it indicates the price at which the director can purchase shares in the future.

Stakeholder Impact

• The acquisition of shares and options by a director can be viewed positively by shareholders, indicating confidence in the company's future.

Key Dates

Keywords

Protagonist Therapeutics, Harold E. Selick, stock options, restricted stock units, insider trading, share acquisition, director, equity